Impurity Profiling and Forced Degradation Guide

The Regulatory Framework: ICH Guidelines for Impurities

The International Council for Harmonisation (ICH) has established a comprehensive framework of guidelines governing pharmaceutical impurities. Understanding this framework is essential for designing studies that meet regulatory expectations and for setting specifications that will withstand scrutiny during review and inspection.

ICH Q3A(R2): Impurities in New Drug Substances

ICH Q3A addresses impurities in new drug substances (APIs) that have not previously been registered. It establishes three critical threshold levels based on the maximum daily dose of the drug substance:

Maximum Daily Dose	Reporting Threshold	Identification Threshold	Qualification Threshold
Up to and including 2 g/day	0.05%	0.10% or 1.0 mg/day intake (whichever is lower)	0.15% or 1.0 mg/day intake (whichever is lower)
Greater than 2 g/day	0.03%	0.05%	0.05%

Reporting threshold: Any impurity at or above this level must be reported in the specification and on the certificate of analysis. Below this level, impurities need not be individually reported (though they contribute to any “total impurities” specification).

Identification threshold: Impurities at or above this level must be structurally identified. This typically requires isolation (by preparative HPLC or other techniques) followed by full structural characterization using mass spectrometry (MS/MS fragmentation), NMR spectroscopy, and comparison with authentic reference standards when available.

Qualification threshold: Impurities at or above this level must be qualified — that is, their safety at the reported level must be demonstrated. Qualification can be achieved through literature review (if the impurity is a known compound with published safety data), through formal toxicological studies (general toxicity, genotoxicity), or through clinical qualification (if patients in clinical trials were exposed to the impurity at or above the specified level).

ICH Q3B(R2): Impurities in New Drug Products

ICH Q3B applies the same threshold framework to degradation products in drug products (finished dosage forms). The thresholds are slightly different because they account for the degradation pathway from the formulated product:

Maximum Daily Dose	Reporting Threshold	Identification Threshold	Qualification Threshold
Up to and including 1 g/day	0.1%	0.2% or 2 mg/day intake (whichever is lower)	0.2% or 2 mg/day intake (whichever is lower)
Greater than 1 g/day and up to 10 mg/day	0.1%	0.2% or 2 mg/day intake (whichever is lower)	0.2% or 2 mg/day intake (whichever is lower)
Greater than 10 mg/day and up to 2 g/day	0.1%	0.2% or 2 mg/day intake (whichever is lower)	0.2% or 2 mg/day intake (whichever is lower)
Greater than 2 g/day	0.05%	0.05%	0.05%

Note that Q3B thresholds are generally higher than Q3A thresholds, reflecting the lower levels of degradation products typically observed in properly stored drug products compared to process-related impurities in drug substances.

ICH Q3C(R8): Residual Solvents

ICH Q3C classifies residual solvents into three categories based on toxicity:

• Class 1 (solvents to be avoided): Benzene (2 ppm limit), carbon tetrachloride (4 ppm), 1,2-dichloroethane (5 ppm), 1,1-dichloroethene (8 ppm), and 1,1,1-trichloroethane (1,500 ppm). These are known human carcinogens or environmental hazards.
• Class 2 (solvents to be limited): Includes methylene chloride (600 ppm), chloroform (60 ppm), methanol (3,000 ppm), acetonitrile (410 ppm), pyridine (200 ppm), and others. PDE-based limits vary by solvent.
• Class 3 (solvents with low toxic potential): Ethanol, acetone, ethyl acetate, isopropanol, and others with PDE values of 50 mg or more per day, corresponding to a general limit of 5,000 ppm.

Residual solvent testing is performed by headspace gas chromatography (HS-GC) or headspace GC-MS, using the manufacturing process description to determine which solvents must be tested. Option 1 (the most common approach) requires testing for each solvent used in the synthesis. Option 2 permits testing only for Class 1 solvents and solvents used in the final purification step if a general residual solvent test (loss on drying) meets an overall limit.

ICH Q3D(R2): Elemental Impurities

ICH Q3D establishes permitted daily exposure (PDE) limits for 24 elemental impurities based on route of administration. Elements are classified into three groups based on likelihood of occurrence:

• Class 1 (arsenic, cadmium, mercury, lead): Toxic elements that require evaluation across all routes of administration. For oral delivery, PDE limits are 15 micrograms/day (As), 5 micrograms/day (Cd), 30 micrograms/day (Hg), and 5 micrograms/day (Pb).
• Class 2A (cobalt, nickel, vanadium): Elements with relatively high probability of occurrence in drug products. Must be evaluated across all potential sources.
• Class 2B (silver, gold, iridium, osmium, palladium, platinum, rhodium, ruthenium, selenium, thallium): Elements with low probability of natural occurrence but that may be introduced as catalysts or reagents. Risk assessment determines whether testing is required.
• Class 3 (barium, chromium, copper, lithium, molybdenum, antimony, tin): Elements with relatively low toxicity by oral route, requiring evaluation only when intentionally added.

Palladium is particularly relevant for pharmaceutical synthesis because palladium-catalyzed cross-coupling reactions (Suzuki, Heck, Buchwald-Hartwig, Sonogashira) are ubiquitous in modern API manufacturing. The oral PDE for palladium is 100 micrograms per day, and demonstrating consistent compliance requires ICP-MS testing of each batch plus a documented control strategy (scavenger resins, activated carbon treatment, crystallization purge). Residual metal control is a critical consideration during process chemistry optimization, where catalyst loading reduction can dramatically simplify downstream purification.

ICH M7(R2): Mutagenic Impurities

ICH M7 establishes a framework for controlling potentially mutagenic impurities — impurities that may cause DNA damage and increase cancer risk. The acceptable intake (AI) for mutagenic impurities is 1.5 micrograms per day for lifetime exposure (corresponding to a theoretical cancer risk of less than 1 in 100,000 over 70 years). For shorter-duration exposure, higher limits apply: 20 micrograms per day for 1-12 months, 60 micrograms per day for 1-12 months during clinical development, and 120 micrograms per day for less than 1 month.

All impurities must be assessed for mutagenic potential through a structured evaluation:

1. Structure-based assessment: Using computational (in silico) toxicology tools (Derek Nexus, Sarah Nexus, Leadscope, or similar validated QSAR systems) to evaluate whether structural alerts for mutagenicity are present
2. Class assignment: Impurities are assigned to one of five classes based on their known or predicted mutagenic and carcinogenic potential
3. Control strategy: Class 1 (known mutagenic carcinogens), Class 2 (known mutagens with unknown carcinogenic potential), and Class 3 (structural alert present, no mutagenicity data) require control to acceptable intake limits. Class 4 (structural alert present but evidence of non-mutagenicity) and Class 5 (no structural alert) are controlled as ordinary impurities per Q3A/Q3B.

Common structural alerts for mutagenicity include alkyl halides, epoxides, aromatic amines, nitroaromatic compounds, aziridines, Michael acceptors, and alkyl sulfonates. Many of these are commonly used reagents or formed as byproducts in pharmaceutical synthesis.

Categories of Pharmaceutical Impurities

A systematic impurity profiling study must consider all categories of impurities that may be present in the drug substance or drug product.

Process-Related Impurities

Process-related impurities originate from the manufacturing process and include:

• Starting materials and intermediates: Unreacted starting materials or incompletely converted intermediates that carry through to the final product. Control is achieved through in-process testing and final product specifications.
• Reagents and ligands: Residual reagents (coupling agents like EDC or HATU, reducing agents like sodium borohydride), catalysts (palladium, rhodium, ruthenium), and ligands (triphenylphosphine, BINAP, dppf) used in the synthesis.
• Byproducts: Compounds formed through alternative reaction pathways — regioisomers from non-selective reactions, diastereomers from incomplete stereochemical control, over-alkylation products, and hydrolysis products.
• Enantiomeric impurity: The undesired enantiomer in a chiral drug substance. Controlled by chiral HPLC or chiral GC methods separate from the achiral impurity profile.

Degradation Products

Degradation products form during storage through chemical decomposition pathways:

• Hydrolysis products: Esters, amides, lactams, lactones, and other hydrolytically labile functional groups cleave in the presence of moisture
• Oxidation products: N-oxides, sulfoxides, peroxides, and hydroxylated products form through autoxidation or peroxide-mediated pathways
• Photodegradation products: UV/visible light-induced rearrangements, bond cleavages, and radical-mediated reactions
• Thermal degradation products: Elimination reactions, retro-Diels-Alder reactions, decarboxylation, and epimerization accelerated by elevated temperature

Interaction/Leachable Impurities

For drug products, impurities may originate from:

• Excipient interactions: Maillard reactions between amine-containing drugs and reducing sugars (lactose), transesterification with polymeric excipients, and acid-base reactions with buffering agents
• Container closure leachables: Compounds extracted from primary packaging materials (rubber stoppers, plastic containers, adhesives, inks) under storage conditions

Forced Degradation Study Design

Forced degradation studies (stress testing) per ICH Q1A(R2) serve two critical purposes: (1) demonstrating the stability-indicating capability of analytical methods, and (2) identifying degradation pathways and products that may form under accelerated or long-term storage conditions.

Study Design Principles

The goal of forced degradation is to achieve 5% to 20% degradation of the drug substance under each stress condition. Less than 5% degradation may be insufficient to detect minor degradation products or to challenge method specificity. More than 20% degradation risks generating secondary degradation products (products of products) that obscure the primary degradation pathway and complicate interpretation.

Forced degradation studies should be conducted on both the drug substance alone and on the drug product (to capture excipient-mediated degradation pathways not observable in the drug substance).

Stress Conditions and Experimental Design

The following table provides a comprehensive forced degradation study design template:

Stress Condition	Typical Conditions	Duration	Target Degradation	Key Controls
Acid hydrolysis	0.1-1.0 N HCl, 25-80 degrees C	1-7 days	5-20%	Blank (acid only), unstressed control
Base hydrolysis	0.1-1.0 N NaOH, 25-80 degrees C	1-7 days	5-20%	Blank (base only), unstressed control
Oxidative	0.3-3% H2O2, 25-80 degrees C	1-7 days	5-20%	Blank (peroxide only), unstressed control
Thermal	60-80 degrees C (solid and solution)	1-4 weeks	5-20%	Unstressed control at 25 degrees C
Photolytic	ICH Q1B: 1.2M lux-hours visible + 200 Wh/m2 UV	Per Q1B	5-20%	Dark control (foil-wrapped)
Humidity	75% RH or 90% RH, 40 degrees C	1-4 weeks	5-20%	Sealed container control
Metal ion catalysis (optional)	0.05 M Fe3+ or Cu2+, 40 degrees C	1-7 days	Variable	Blank (metal salt only)

Acid and Base Hydrolysis

Acid and base hydrolysis studies probe the susceptibility of the molecule to pH-dependent degradation. Start with mild conditions (0.1 N acid or base at 25 degrees C for 24 hours) and escalate progressively if insufficient degradation is observed. Common functional groups susceptible to hydrolysis include:

• Esters: Hydrolyzed to carboxylic acids and alcohols. Both acid- and base-catalyzed. Base hydrolysis (saponification) is typically faster.
• Amides: Generally more stable than esters but hydrolyzable under forcing conditions. Lactams (cyclic amides) may be more susceptible due to ring strain.
• Lactones: Ring-opening hydrolysis to hydroxy acids. Often pH-sensitive.
• Imines (Schiff bases): Hydrolyzed to aldehydes/ketones and amines. Acid-catalyzed.
• Carbamates: Hydrolyzed to amines and carbon dioxide.
• Sulfonate esters: Hydrolyzed to sulfonic acids and alcohols.

For each study, the stress solution must be neutralized (for acid/base studies) or quenched (for oxidative studies) before analysis to prevent ongoing degradation during the analytical run.

Oxidative Degradation

Hydrogen peroxide (H2O2) is the standard oxidizing agent for forced degradation studies. Concentrations of 0.3% to 3% (w/v) are typical. Begin with 0.3% at 25 degrees C and increase if necessary.

Functional groups particularly susceptible to oxidation include:

• Thioethers: Oxidized to sulfoxides, then further to sulfones. This is one of the most common pharmaceutical degradation pathways (observed in omeprazole, rabeprazole, and many thioether-containing drugs).
• Tertiary amines: Oxidized to N-oxides. Clinically relevant for many CNS drugs and antihistamines.
• Indoles and pyrroles: Susceptible to ring oxidation and ring-opening reactions.
• Benzylic and allylic positions: Susceptible to autoxidation through radical chain mechanisms.
• Aldehydes: Oxidized to carboxylic acids (Cannizzaro-type disproportionation or direct oxidation).

Oxidative degradation can also be studied using free radical initiators (AIBN — azobisisobutyronitrile) to simulate autoxidation pathways more realistically than peroxide-mediated oxidation.

Thermal Degradation

Thermal degradation studies are conducted on solid drug substance (stored in open containers at 60-80 degrees C) and on drug substance in solution (heated at 40-80 degrees C in sealed containers). The comparison between solid-state and solution-state thermal degradation reveals whether the crystal lattice provides protection against degradation pathways that are active in solution.

Photolytic Degradation

Photostability testing per ICH Q1B requires exposure to an overall illumination of not less than 1.2 million lux-hours and an integrated near-ultraviolet energy of not less than 200 watt-hours per square meter. This can be achieved using Option 1 (a combination of cool white fluorescent and near-UV fluorescent lamps) or Option 2 (a xenon or metal halide lamp simulating full-spectrum daylight).

Both a light-exposed sample and a dark control (identical sample wrapped in aluminum foil and exposed alongside the test sample) must be analyzed. Any difference in degradation between the exposed and dark control samples is attributed to photodegradation.

Analytical Methods for Impurity Profiling

Stability-Indicating HPLC Methods

The primary analytical method for impurity profiling must be demonstrated to be stability-indicating — capable of resolving the drug substance peak from all known process impurities and degradation products. This is demonstrated by analyzing forced degradation samples and confirming that:

1. The drug substance peak is resolved (resolution factor Rs greater than or equal to 1.5) from all degradation product peaks
2. No co-eluting peaks are hidden under the drug substance peak (confirmed by peak purity analysis using diode array detection or mass spectrometric detection)
3. The method detects all significant degradation products (mass balance assessment)

Method development for stability-indicating HPLC typically involves screening multiple columns (C18, C8, phenyl-hexyl, polar-embedded), mobile phase pH values (2.0, 4.5, 6.8), organic modifiers (acetonitrile, methanol), and gradient profiles to achieve adequate separation of all peaks. Modern approaches use automated method screening platforms (Waters ACQUITY AutoBlend, Agilent Method Scouting) to evaluate 20-50 conditions in 2-3 days. Organizations outsourcing analytical testing should verify that their contract lab has these automated screening capabilities.

Peak Purity Assessment

Peak purity assessment confirms that a chromatographic peak represents a single chemical entity rather than two or more co-eluting compounds. Two complementary approaches are standard:

• Diode array detection (DAD) purity: Compares UV spectra across the peak (upslope, apex, downslope). Spectral homogeneity — quantified as a purity angle less than the purity threshold — indicates no spectrally distinct co-eluting impurity. Limitation: cannot detect co-eluting compounds with identical UV spectra.
• Mass spectrometric peak purity: Examines extracted ion chromatograms across the peak. The presence of ions not attributable to the main compound indicates co-elution. More definitive than DAD purity but requires LC-MS capability.

Peak purity assessment is required for the drug substance peak in all forced degradation samples to confirm that apparent stability (no decrease in area%) is not an artifact of a co-eluting degradation product compensating for drug substance loss.

Mass Balance Assessment

Mass balance is the most rigorous test of a forced degradation study’s completeness. It compares the sum of the drug substance remaining plus all detected degradation products against the initial drug substance content:

Mass balance (%) = Drug substance remaining (%) + Sum of all degradation products (%)

Acceptable mass balance is typically 90% to 110% for most forced degradation conditions. Poor mass balance (below 90%) indicates that degradation products are not being detected — they may be non-chromophoric (invisible to UV detection), volatile (lost during sample preparation), retained on the column, or precipitated out of solution. When mass balance is poor, additional detection techniques must be employed:

• Charged aerosol detection (CAD) or ELSD for non-chromophoric degradants
• Headspace GC for volatile degradation products
• LC-MS total ion chromatogram for comprehensive detection regardless of chromophore

Identification of Unknown Impurities

When an impurity exceeds the ICH identification threshold but does not match any known process impurity or predicted degradation product, structural identification becomes necessary. The workflow typically proceeds as follows:

1. Accurate mass determination by high-resolution mass spectrometry (HRMS — QTOF or Orbitrap) to determine molecular formula
2. MS/MS fragmentation to elucidate structural features and identify the relationship to the parent drug substance
3. Preparative isolation by preparative HPLC to obtain sufficient material for NMR
4. NMR characterization (1H, 13C, COSY, HSQC, HMBC) for complete structural assignment
5. Synthesis of authentic reference standard to confirm identity and enable quantitative analysis

This identification workflow typically requires 4 to 12 weeks per unknown impurity, depending on the quantity of material available for isolation and the structural complexity of the impurity. ChemContract’s analytical services team provides end-to-end impurity identification from HRMS through reference standard synthesis. For drug products near the end of development, unidentified impurities above the identification threshold can delay regulatory submissions by months.

Example Forced Degradation Study Report Structure

A well-structured forced degradation study report enables regulatory reviewers to assess the quality and completeness of the study efficiently. The following structure reflects current regulatory expectations:

Report Section 1: Study Objective and Scope

Define whether the study covers the drug substance, drug product, or both. State the regulatory context (IND-enabling, NDA/ANDA submission support) and the specific objectives (method specificity demonstration, degradation pathway identification, mass balance assessment).

Report Section 2: Materials and Methods

Document the drug substance lot, purity, and storage conditions; stress reagent concentrations and sources; analytical method parameters (column, mobile phase, gradient, detection wavelength, injection volume); and reference standard information.

Report Section 3: Results by Stress Condition

For each stress condition, report:

• Extent of degradation (percent drug substance remaining)
• Individual degradation products detected (retention time, relative retention time, area%)
• Peak purity results for the drug substance peak
• Mass balance calculation
• Comparison to unstressed control

Report Section 4: Degradation Pathway Summary

Compile all degradation products observed across all conditions into a single summary table:

Degradation Product	RRT	Stress Condition	Maximum Level Observed	Proposed Structure	Identification Method
DP-1	0.72	Base hydrolysis	3.2%	Des-methyl acid	LC-MS/MS, NMR
DP-2	0.85	Oxidative (H2O2)	5.8%	N-oxide	LC-MS/MS, comparison to standard
DP-3	1.15	Photolytic	1.4%	Dechlorinated product	HRMS (proposed)
DP-4	1.32	Acid hydrolysis	2.1%	Ring-opened lactam	LC-MS/MS, NMR

Report Section 5: Method Specificity Conclusion

State whether the analytical method resolves all detected degradation products from the drug substance peak, with supporting chromatographic evidence (overlay of stressed and unstressed chromatograms, resolution calculations, peak purity data).

Report Section 6: Recommendations

Identify degradation products that require monitoring in formal stability studies, recommend specification limits based on observed degradation rates, and flag any degradation products requiring identification or qualification per ICH thresholds.

Common Pitfalls in Forced Degradation Studies

Over-Degradation

Excessive degradation (greater than 30-50%) generates secondary and tertiary degradation products that obscure primary pathways and complicate the degradation profile. Over-degradation can also cause precipitation of insoluble degradation products, leading to poor mass balance and misleading chromatographic profiles. Always begin with mild conditions and escalate incrementally.

Inadequate Controls

Every stress study requires both an unstressed control (same solution composition, stored at ambient conditions for the same duration) and appropriate blanks (stress reagent without drug substance). Without these controls, peaks from reagent degradation, solvent impurities, or container extractables may be misidentified as drug degradation products.

Ignoring Solution vs. Solid-State Differences

Drug substances may degrade through different pathways in solution versus the solid state. Forced degradation studies conducted only in solution may miss solid-state-specific degradation (epimerization in crystals, surface oxidation, hydrate formation/loss) that becomes relevant during formal stability studies on the solid drug substance.

Overlooking Non-Chromophoric Degradants

UV-based HPLC detection is the default analytical approach, but it is blind to degradation products lacking UV chromophores. If a compound undergoes a degradation reaction that destroys the chromophore (ring fragmentation, reductive elimination of an aromatic group), the resulting product will be undetected by UV, leading to poor mass balance and a false sense of stability. Always supplement UV detection with a universal detector (CAD, ELSD, or MS total ion current) for at least one representative stressed sample.

Failure to Assess Excipient Interactions

For drug product forced degradation, excipient-mediated degradation pathways must be evaluated. Binary mixtures of drug substance with each excipient, stressed at 40 degrees C / 75% RH for 2-4 weeks, can reveal incompatibilities not observed in the drug substance alone. The classic example is the Maillard reaction between primary amine drugs and lactose, producing brown discoloration and glycosylamine degradation products.

Connecting Impurity Profiling to Specifications and Control Strategy

The ultimate purpose of impurity profiling and forced degradation studies is to establish a scientifically justified control strategy: a set of specifications, analytical methods, and manufacturing controls that ensure every batch meets quality requirements throughout its shelf life.

The control strategy should address:

• Specified impurities: Known impurities that are individually named and limited. These include process impurities consistently observed above the reporting threshold and degradation products identified in stability studies above the reporting threshold.
• Unspecified impurities: An acceptance criterion for any individual impurity not individually listed (typically set at the identification threshold).
• Total impurities: A cumulative limit for all impurities. Typically 1.0% to 2.0% for drug substances, depending on the compound and therapeutic context.
• Mutagenic impurities: Controlled per ICH M7, with compound-specific or class-specific limits based on acceptable intake calculations.
• Elemental impurities: Controlled per ICH Q3D, with testing or risk-assessment-based justification for each element.
• Residual solvents: Controlled per ICH Q3C, with testing based on solvents used in the manufacturing process.

A well-designed control strategy is not merely a list of tests — it is a scientific argument demonstrating that the combination of process controls, in-process testing, and final product specifications ensures patient safety. Regulatory reviewers evaluate the coherence of this argument, and gaps or inconsistencies invite deficiency letters and delays.

Frequently Asked Questions

What is the difference between impurity profiling and forced degradation studies?

Impurity profiling identifies and quantifies all impurities present in a drug substance or drug product, including process-related impurities, degradation products, and residual solvents. Forced degradation studies intentionally stress the compound under extreme conditions (acid, base, oxidation, heat, light) to identify degradation pathways and demonstrate that analytical methods can detect all degradation products.

What are the ICH reporting thresholds for pharmaceutical impurities?

For drug substances with a maximum daily dose up to 2 g/day, the reporting threshold is 0.05%, the identification threshold is 0.10% (or 1.0 mg/day, whichever is lower), and the qualification threshold is 0.15% (or 1.0 mg/day, whichever is lower). For daily doses exceeding 2 g/day, all three thresholds tighten to 0.03-0.05%.

How much degradation should a forced degradation study achieve?

Target 5-20% degradation under each stress condition. Less than 5% degradation may be insufficient to detect minor degradation products or challenge method specificity. More than 20% degradation generates secondary and tertiary degradation products that obscure primary pathways and complicate interpretation. Always start with mild conditions and escalate incrementally.

What is mass balance in forced degradation studies and why does it matter?

Mass balance compares the sum of remaining drug substance plus all detected degradation products against the initial content. Acceptable mass balance is 90-110%. Poor mass balance (below 90%) indicates degradation products are going undetected — they may be non-chromophoric, volatile, or retained on the column. Supplemental detection techniques like charged aerosol detection or LC-MS are needed when UV-based mass balance is poor.

How long does it take to identify an unknown pharmaceutical impurity?

The full identification workflow — HRMS molecular formula determination, MS/MS fragmentation, preparative HPLC isolation, NMR characterization, and reference standard synthesis — typically requires 4-12 weeks per unknown impurity. Timeline depends on the quantity of material available for isolation and the structural complexity. Starting impurity profiling early in development avoids last-minute surprises that delay regulatory submissions.

How ChemContract Supports Impurity Profiling and Forced Degradation Studies

ChemContract’s analytical services team provides comprehensive impurity profiling and forced degradation study support for pharmaceutical development programs at every stage — from early-phase IND-enabling studies through NDA/ANDA submission packages.

• Full forced degradation study design and execution across all ICH-recommended stress conditions (acid, base, oxidative, thermal, photolytic, humidity), with systematic escalation protocols to achieve target degradation levels
• Stability-indicating HPLC method development and validation per ICH Q2(R2), with automated method screening across columns, pH, and gradient conditions
• Peak purity assessment by DAD and LC-MS to confirm method specificity
• Mass balance assessment using complementary detection techniques (UV, CAD, MS) to ensure complete degradation product accounting
• Unknown impurity identification by HRMS, MS/MS fragmentation, preparative isolation, and full NMR characterization
• Elemental impurity analysis by ICP-MS per ICH Q3D, with risk assessment and control strategy development
• Residual solvent analysis by headspace GC and GC-MS per ICH Q3C
• Mutagenic impurity assessment per ICH M7, including in silico QSAR evaluation, analytical method development for trace-level quantitation, and control strategy design
• Comprehensive study reports formatted for direct incorporation into CTD Module 3 regulatory submissions
• Contract R&D integration — our analytical and synthetic chemistry teams collaborate to trace impurity origins, design purge strategies, and optimize processes to minimize impurity formation at the source

For pharmaceutical development teams seeking a partner that combines deep analytical expertise with practical regulatory knowledge, ChemContract delivers impurity profiling and forced degradation studies that build the scientific foundation for successful regulatory submissions. Contact our team to discuss your impurity profiling needs.